Viracta Therapeutics Inc (NASDAQ: VIRX): The Best-Of-Breed For Investing?
Currently, there are 39.09M common shares owned by the public and among those 27.71M shares have been available to trade. The company’s stock has a 5-day price change of -3.12% and -51.56% over the past three months. VIRX shares are trading -59.21% year to date (YTD), with the 12-month market performance down to -63.67% lower. […]
